Volume 8, Supplement 7 (Dec 2017)
CLL is the most common leukemia in Western countries, with a population primarily over 70 years of age. Frailty and comorbidities are common concerns with established chemoimmunotherapy, but new FDA-approved therapies have led to specialized, specific treatments for the different stages of CLL.
